In re BioClinica, Inc. Shareholder Litigation, C.A. No. 8272-VCG (Del. Ch. Feb. 25, 2013). This Chancery ruling denied a motion to expedite claims in consolidated cases that were quickly filed to challenge the merger of BioClinica with JLL Partners. The court explained the basis for the denial as the absence of any colorable claims. In addition to being a useful update for the standards that apply to this type of motion, commentators have observed that denying motions to expedite, when warranted, is one approach to imposing greater control over the burgeoning number of suits in multiple jurisdictions that challenge 90% or more of all mergers involving $100 million or more.